Trials / Withdrawn
WithdrawnNCT03996486
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
A Multicenter, Non-randomized, Open-label, Multiple Dose Escalation Study to Evaluate the Safety and Tolerability of Subcutaneous BAY1093884 in Males With Severe Hemophilia
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety of a test drug to treat hemophilia in adult men.
Detailed description
The primary objective is to assess the safety of multiple doses of BAY1093884.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY1093884 | Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses) |
Timeline
- Start date
- 2019-10-28
- Primary completion
- 2020-05-29
- Completion
- 2020-07-31
- First posted
- 2019-06-24
- Last updated
- 2019-10-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03996486. Inclusion in this directory is not an endorsement.